Product Description
Mechanisms of Action: KAR Antagonist, AMPA Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Migraine Disorders|Adrenocortical Adenoma|Sarcoma, Endometrial Stromal|Seizures|Adenoma|Tinnitus|Epilepsy, Reflex|Multiple Sclerosis|Epilepsy|Muscle Spasticity|Migraine without Aura|Migraine with Aura
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12621000138886p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Depressive Disorder |
2021-05-28 |
|||
NCT01649050 |
CBGG492A2215 | P2 |
Withdrawn |
Multiple Sclerosis|Muscle Spasticity |
2018-03-01 |
2019-03-19 |
Treatments |
|
NCT01617941 |
CBGG492A2214 | P2 |
Withdrawn |
Migraine Disorders |
2016-11-01 |
2019-03-19 |
||
2013-003431-29 |
2013-003431-29 | P2 |
Completed |
Adenoma |
2015-09-21 |
2022-03-13 |
Treatments |
|
NCT02150213 |
CBGG492A2216 | P2 |
Completed |
Sarcoma, Endometrial Stromal|Adrenocortical Adenoma |
2015-09-01 |
2019-03-20 |
Treatments |
|
2011-005316-28 |
2011-005316-28 | P2 |
Terminated |
Migraine with Aura|Migraine Disorders|Migraine without Aura |
2013-04-05 |
2022-03-13 |
Treatments |
|
2010-021448-17 |
2010-021448-17 | P2 |
Completed |
Epilepsy |
2012-07-04 |
2022-03-13 |
Treatments |
|
NCT01338805 |
CBGG492A2212 | P2 |
Completed |
Seizures |
2012-07-01 |
2021-03-06 |
Primary Endpoints|Treatments |
|
2010-022166-27 |
2010-022166-27 | P2 |
Completed |
Tinnitus |
2012-01-31 |
2022-03-13 |
Treatments |
|
NCT01302873 |
CBGG492A2210 | P2 |
Completed |
Tinnitus |
2012-01-01 |
2019-03-19 |
Treatments |
|
2009-017961-52 |
2009-017961-52 | P2 |
Completed |
Seizures |
2011-09-26 |
2022-03-13 |
Treatments |
|
NCT01147003 |
CBGG492A2207 | P2 |
Completed |
Seizures |
2011-09-01 |
2019-03-19 |
||
2010-018766-23 |
2010-018766-23 | P2 |
Terminated |
Unknown |
2010-11-08 |
2025-07-05 |
Treatments |
|
NCT01167335 |
CBGG492A2211 | P2 |
Withdrawn |
Seizures |
2010-11-01 |
2019-03-19 |
||
NCT00784212 |
CBGG492A2203 | P2 |
Completed |
Epilepsy, Reflex |
2010-09-01 |
2019-03-18 |
Treatments |
|
2008-005392-10 |
2008-005392-10 | P2 |
Completed |
Migraine Disorders |
2010-08-24 |
2022-03-12 |
||
2008-005065-64 |
2008-005065-64 | P2 |
Completed |
Epilepsy |
2010-08-05 |
2025-06-08 |
Treatments |
|
NCT00892203 |
CBGG492A2204 | P2 |
Completed |
Migraine Disorders |
2010-08-01 |
2019-03-18 |
Treatments |
|
NCT00887861 |
CBGG492A2202 | P2 |
Completed |
Epilepsy |
2010-08-01 |
2019-03-18 |
Treatments |